It only makes sense to have an alternative, traditional vaccine, available to meet healthcare demands, in the event that mRNA vaccine manufacturers withdraw from the market, when PREP Act protection expires. The only traditional vaccine approved for use in the US is the Novavax vaccine. If the safety and efficacy of that vaccine proves to be enhanced by Humanigen's patented methodology, using lenzilumab, then the company needs to be prepared to meet that demand.
Not only is the subject germane, the issue is critical. We cannot let a highly lethal virus attach to receptor cells, and if they do, we need to combat the effects of that infection vigorously and effectively, using lenzilumab, in both processes. Lenzilumab showed outstanding results when administered early. The LIVE-AIR trial met the primary endpoint, and those results have been peer-reviewed by both Lancet and Thorax. The company has a history of treatment data for the product, even preceding Covid.
"Research into Disease X also requires gain-of-function utilization, to possibly produce another novel coronavirus, which I think could be the Pangolin Coronavirus GX_P2V..."
More recent discussion suggests that "Disease X" could actually prove to be a version of H5N1 bird flu, which could be, or will become, genetically modified. Dr. Kelly Victory, one of my favorites, conducted an excellent interview of Dr. Brian Hooker, PhD, on this subject of "H5N1 Bird Flu: New Pandemic Gets New mRNA Vaccine," starting at minute marker 09:30 in the following video.
However, I don't think this is necessarily going to be a lather-rinse-repeat of what we have seen in the programmed governmental response to covid.
I'm glad to see that Sanofi acknowledged their co-exclusive licensing agreement with Novavax yesterday.
I was hoping that we would finally hear from Humanigen/Taran that lenz is the product being licensed to Sanofi and Novavax for their covid and covid/flu vaccines. For that matter, I'd like to see that Gracell and Mayo Clinic may also announce co-exclusive licensing of lenz for their CAR-T platforms.
The point is, that while regulators will likely continue to push for mRNA vaccines for their sponsors' covid/flu products, trials are underway for Novavax/Sanofi to use traditional vaccine technology, hopefully enhanced by lenz.
Billions of covid revenue dollars are at stake for Humanigen/Taran, along with Sanofi and Novavax. I think management has captured that opportunity for us. I think we should know by the 13th, perhaps earlier if the Liquidating Trust is dissolved.
News 
Market Data 
Discover 
